<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845582</url>
  </required_header>
  <id_info>
    <org_study_id>ALK001-P3001</org_study_id>
    <nct_id>NCT03845582</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of ALK-001 in Geographic Atrophy</brief_title>
  <acronym>SAGA</acronym>
  <official_title>A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkeus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkeus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-masked, multicenter, randomized, placebo-controlled clinical trial,&#xD;
      evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA)&#xD;
      secondary to age-related macular degeneration (AMD).&#xD;
&#xD;
      Up to 200 participants will receive ALK-001 while up to 100 participants will receive a&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no treatment available for Geographic Atrophy secondary to AMD. AMD is characterized&#xD;
      by an age-related degeneration of the retina.&#xD;
&#xD;
      The root cause for this degeneration or why some people develop AMD while others do not, is&#xD;
      unknown. Over 20 years ago, it was hypothesized that the dimerization of vitamin A may be a&#xD;
      significant contributor to the etiology of AMD. The eye indeed uses vitamin A as a cofactor&#xD;
      to sense light, and a striking chemical signature of the aging and degenerating retina is the&#xD;
      accumulation of vitamin A dimers in the retinal pigment epithelium (RPE) and the underlying&#xD;
      Bruch's membrane. In rodent models, high levels of vitamin A dimers correlate with poor&#xD;
      retinal health, and a variety of mechanisms have been proposed by which vitamin A dimers may&#xD;
      induce retinal toxicity. It has been argued that these mechanisms participate in the&#xD;
      development and progression of AMD.&#xD;
&#xD;
      ALK-001, the study drug, is a modified form of vitamin A. When taken once a day as a capsule,&#xD;
      it replaces natural vitamin A in the body with one that forms vitamin A dimers more slowly.&#xD;
      This study will measure the extent to which treatment with ALK-001 slows the progression of&#xD;
      Geographic Atrophy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth rate of GA lesions, as assessed by Fundus Autofluorescence (FAF)</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, as assessed by evaluation of adverse events</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, as assessed by plasma concentrations of ALK-001 and metabolites</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of choroidal neovascularization (CNV)</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Acuity</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Reading Speed</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Age Related Macular Degeneration</condition>
  <condition>AMD</condition>
  <condition>Atrophy, Geographic</condition>
  <arm_group>
    <arm_group_label>ALK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK-001 oral capsule</intervention_name>
    <description>Daily administration for 24 months</description>
    <arm_group_label>ALK-001</arm_group_label>
    <other_name>C20-D3-Retinyl Acetate</other_name>
    <other_name>C20 Deuterated vitamin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Daily administration for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
        - At least one eye with geographic atrophy secondary to dry age-related macular&#xD;
        degeneration (AMD)&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
        - Medical condition, which may interfere with the progression of GA, prevent performance of&#xD;
        study procedures, compliance with protocol, or continuous participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonide Saad, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alkeus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coordinating Center</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-7965. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.</citation>
    <PMID>21075840</PMID>
  </reference>
  <reference>
    <citation>Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-Dâ‚ƒ-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.</citation>
    <PMID>23914132</PMID>
  </reference>
  <reference>
    <citation>Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.</citation>
    <PMID>26427432</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

